Trial Profile
Irinotecan and Temozolomide for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2023
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Temozolomide (Primary) ; Vincristine (Primary)
- Indications Ewing's sarcoma
- Focus Therapeutic Use
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 31 Oct 2022 Planned number of patients changed from 102 to 60.
- 31 Oct 2022 Planned primary completion date changed from 28 Feb 2020 to 28 Nov 2022.